| 7BGQ |
1.75 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1019 |
| 6YOX |
2.05 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027 |
| 4FR3 |
1.9 |
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer 16-O-Me-FC-H |
| 7NZK |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121 |
| 7O3R |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042 |
| 7BI3 |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179 |
| 7OQJ |
1.4 |
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ162 |
| 7NM1 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126 |
| 7O5A |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158 |
| 3SMM |
2.0 |
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fusicoccin J aglycone |
| 7O5S |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167 |
| 7BA3 |
1.4 |
Cys-42-tethered stabilizer 6 of 14-3-3(sigma)/ERa PPI |
| 7OQW |
1.9 |
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ178 |
| 6FBW |
1.45 |
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-II with 14-3-3sigma |
| 5HF3 |
1.8 |
Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma |
| 7NK5 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124 |
| 7NJA |
1.75 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1006 |
| 6RJQ |
1.885 |
Fragment AZ-006 binding at the TAZpS89/14-3-3 sigma interface |
| 3IQU |
1.05 |
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) |
| 6RKK |
1.88 |
Fragment AZ-021 binding at the p53pT387/14-3-3 sigma interface |
| 4DAT |
1.4 |
Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif II |
| 5BTV |
1.7 |
Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS324 |
| 3P1R |
1.7 |
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide |
| 6YOW |
1.23 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521 |
| 7ZMW |
1.8 |
14-3-3s binding to non-natural peptide 2c |
| 8B5P |
1.4 |
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 10 |
| 7BM9 |
1.8 |
Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide |
| 7OQU |
1.4 |
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ180 |
| 7NZV |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120 |
| 3SML |
1.9 |
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer Fusicoccin A aglycone |
| 6YIA |
1.3 |
14-3-3 sigma in complex with SMAD2 pS465 peptide |
| 6S40 |
1.9 |
Fragment AZ-001 binding at the p53pT387/14-3-3 sigma interface and additional sites |
| 7O34 |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043 |
| 7O57 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157 |
| 7NXT |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183 |
| 7NRK |
1.75 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1002F1 |
| 6FAW |
1.4 |
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2c-I with 14-3-3sigma |
| 6Y3W |
1.34 |
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 1 |
| 7O6G |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176 |
| 7BDT |
1.75 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1009 |
| 6QHM |
1.25 |
14-3-3 sigma with RelA/p65 binding site pS281 |
| 6FI4 |
2.0 |
Crystal structure of C-terminal modified Tau peptide-hybrid 3.2e with 14-3-3sigma |
| 7QIP |
2.65 |
SARS-CoV-2 Nucleocapsid phosphopeptide 201-210 bound to human 14-3-3 sigma |
| 5N75 |
1.803 |
14-3-3 sigma in complex with TAZ pS89 peptide |
| 7O5U |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168 |
| 6TL3 |
2.455 |
Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma stabilized by a Pyrrolidone1 derivative |
| 6ZVB |
2.51 |
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 24h incubation |
| 7NZ6 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125 |
| 7NND |
1.4 |
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 09 |
| 6QDU |
1.632 |
Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide inhibited by semi-synthetic fusicoccane FC-NCPC |
| 7O5F |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161 |
| 7O3Q |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041 |
| 6RKM |
1.88 |
Fragment AZ-022 binding at the p53pT387/14-3-3 sigma interface |
| 3T0M |
1.62 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 7ZMU |
1.6 |
14-3-3s binding to non-natural peptide 2d |
| 5MHC |
1.2 |
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
| 7OBH |
2.0 |
Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide and stabilizer Fusicoccin-A |
| 6QZR |
2.3 |
14-3-3 sigma in complex with FOXO1 pT24 peptide |
| 6RL6 |
1.6 |
Fragment AZ-024 binding at the p53pT387/14-3-3 sigma interface |
| 6FAV |
1.4 |
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-I with 14-3-3sigma |
| 7O6I |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085 |
| 7BIQ |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180 |
| 7ORS |
1.8 |
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ147 |
| 6YR6 |
1.75 |
14-3-3 sigma in complex with hDM2-186 peptide |
| 7NMA |
1.75 |
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide |
| 7OBY |
2.1 |
Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide and stabilizer Fusicoccin-A |
| 7OBL |
1.8 |
Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide and stabilizer Fusicoccin-A |
| 7O5G |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164 |
| 5OEH |
2.35 |
Molecular tweezers modulate 14-3-3 protein-protein interactions. |
| 7O3P |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116 |
| 6RJZ |
1.58 |
Fragment AZ-015 binding at the p53pT387/14-3-3 sigma interface |
| 6YLU |
1.88 |
14-3-3sigma in complex with BLNKpT152 phosphopeptide crystal structure |
| 6XXC |
1.3 |
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 4 |
| 6XWD |
1.6 |
14-3-3 sigma bound to canonical mono-phosphorylated aminopeptidase N (APN, CD13) binding motif |
| 6YE9 |
1.8 |
Small-molecule inhibitor of 14-3-3 protein-protein interactions |
| 4DHR |
1.4 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 6SLX |
1.80005 |
Fragment AZ-010 binding at the TAZpS89/14-3-3 sigma interface |
| 6RWU |
1.46 |
Fragment AZ-010 binding at the p53pT387/14-3-3 sigma interface |
| 7BAA |
1.1 |
Cys-42-tethered stabilizer 12 of 14-3-3(sigma)/ERa PPI |
| 6YP3 |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028 |
| 7NLE |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118 |
| 7B9R |
1.15 |
Cys-45-tethered stabilizer 4 of 14-3-3(sigma)/ERa PPI |
| 7ORH |
1.8 |
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ178 |
| 7OB5 |
1.8 |
Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide |
| 7O6O |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096 |
| 7NZG |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122 |
| 7O5X |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173 |
| 7QIK |
2.01 |
SARS-CoV-2 Nucleocapsid phosphopeptide 193-200 bound to human 14-3-3 sigma |
| 7NPG |
1.37 |
Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 22 |
| 7BAB |
1.3 |
Cys-42-tethered stabilizer 13 of 14-3-3(sigma)/ERa PPI |
| 7OBD |
2.0 |
Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide and stabilizer Fusicoccin-A |
| 6YR7 |
2.105 |
14-3-3 sigma in complex with hDMX-342+367 peptide |
| 7OBX |
1.8 |
Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide |
| 7OBT |
2.3 |
Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide and stabilizer Fusicoccin-A |
| 5OEG |
3.15 |
Molecular tweezers modulate 14-3-3 protein-protein interactions |
| 7NSV |
1.33 |
14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046 |
| 7B9M |
1.7 |
Cys-45-tethered stabilizer 3 of 14-3-3(sigma)/ERa PPI |
| 4DHQ |
1.75 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 7OBS |
1.8 |
Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide |
| 7BDY |
1.801 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068B |
| 4DHO |
1.7 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 7OBC |
1.9 |
Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide |
| 6YIC |
1.6 |
14-3-3 sigma in complex with SMAD4 pS403 peptide |
| 7O5C |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159 |
| 6Y3S |
1.95 |
14-3-3 Sigma in complex with phosphorylated (pS210) Gab2 peptide |
| 6YOY |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025 |
| 3IQV |
1.2 |
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) and stabilisator Fusicoccin |
| 7BFW |
1.8 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068A |
| 6QDT |
1.702 |
Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide |
| 6FAU |
1.25 |
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2e-I with 14-3-3sigma |
| 6ZVD |
2.5 |
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 96h incubation |
| 6HKF |
1.801 |
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 4 |
| 6Y8B |
1.54 |
14-3-3 Sigma in complex with phosphorylated caspase{pS139} peptide |
| 3IQJ |
1.15 |
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (10mer) |
| 7BJL |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142 |
| 5OK9 |
2.35 |
CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with swapped phosphopeptides |
| 7NP2 |
1.27 |
Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide |
| 7AEW |
1.2 |
14-3-3 sigma bound to bis-phosphorylated aminopeptidase N (APN, CD13) via canonical and non-canonical binding motifs |
| 4JC3 |
2.05 |
14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface |
| 6RK8 |
1.602 |
Fragment AZ-014 binding at the p53pT387/14-3-3 sigma interface |
| 7AZ1 |
1.15 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1013 |
| 7BJB |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044 |
| 6Y44 |
1.71 |
14-3-3 Sigma in complex with phosphorylated SOS1 peptide |
| 3P1N |
1.4 |
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide |
| 7BA7 |
1.45 |
Cys-42-tethered stabilizer 9 of 14-3-3(sigma)/ERa PPI |
| 6FBB |
1.3 |
Crystal structure of 14-3-3 sigma in complex with wild-type Shroom3 |
| 7NWS |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185 |
| 6Y7T |
2.5 |
Engineered conjugation of lysine-specific molecular tweezers with ExoS derived peptidic inhibitor enhance affinity towards target protein 14-3-3 through ditopic binding |
| 6RX2 |
1.82 |
Fragment AZ-005 binding at the p53pT387/14-3-3 sigma interface |
| 6RL3 |
1.3 |
Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface |
| 7BGW |
1.9 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1011 |
| 6S9Q |
1.69 |
Fragment AZ-004 binding at a primary and secondary site in a p53pT387/14-3-3 complex |
| 7NY4 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130 |
| 3LW1 |
1.28 |
Binary complex of 14-3-3 sigma and p53 pT387-peptide |
| 6RL4 |
1.6 |
Fragment AZ-025 binding at the p53pT387/14-3-3 sigma interface |
| 6QDS |
1.72 |
Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide stabilized by semi-synthetic fusicoccane FC-NCPC |
| 5OMA |
3.9 |
CH3 chimera of human 14-3-3 sigma with the StARD1 peptide including Ser57 |
| 6Y8E |
1.42 |
14-3-3 Sigma in complex with phosphorylated MLF1 peptide |
| 7ORG |
1.8 |
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ162 |
| 7NYG |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127 |
| 7NPB |
1.37 |
Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 09 |
| 7BDP |
1.75 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1017 |
| 6GHP |
1.95 |
14-3-3sigma in complex with a TASK3 peptide stabilized by semi-synthetic natural product FC-NAc |
| 6TCH |
1.801 |
Binary complex of 14-3-3 sigma and a high-affinity non-canonical 9-mer peptide binder |
| 5LU2 |
2.5 |
Human 14-3-3 sigma complexed with long HSPB6 phosphopeptide |
| 7NMX |
2.3 |
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 12 |
| 6RM5 |
1.884 |
Fragment AZ-016 binding at the p53pT387/14-3-3 sigma interface |
| 6G8Q |
1.85 |
14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide |
| 3SPR |
1.99 |
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer FC-THF |
| 7O6F |
2.0 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178 |
| 6ZCJ |
1.53 |
14-3-3sigma in complex with SLP76pS376 phosphopeptide crystal structure |
| 7BIY |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175 |
| 6NV2 |
1.13 |
14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005 |
| 6RWS |
1.53 |
Fragment AZ-009 binding at the p53pT387/14-3-3 sigma interface |
| 6RP6 |
1.885 |
Fragment AZ-019 binding at the TAZpS89/14-3-3 sigma interface |
| 4FL5 |
1.9 |
Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS214 |
| 7OR7 |
1.8 |
Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ178 |
| 6ZVE |
2.51 |
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 1h incubation |
| 7B9T |
1.15 |
Cys-45-tethered stabilizer 5 of 14-3-3(sigma)/ERa PPI |
| 5N5W |
1.37 |
14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV3 |
| 6QIU |
1.802 |
Crystal structure of 14-3-3 sigma in complex with Ataxin-1 Ser776 phosphopeptide |
| 3U9X |
1.8 |
Covalent attachment of pyridoxal-phosphate derivatives to 14-3-3 proteins |
| 6TJM |
1.85 |
Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma stabilized by Pyrrolidone1 |
| 6HN2 |
1.7 |
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 5 |
| 6Y18 |
1.3 |
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 3 |
| 7O5D |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160 |
| 7AOG |
1.5 |
14-3-3 sigma in complex with Pin1 binding site pS72 |
| 6G8P |
1.9 |
14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide |
| 7O6M |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097 |
| 6Y3V |
1.499 |
14-3-3 Sigma in complex with phosphorylated c-Jun peptide |
| 7NJ9 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133 |
| 6RWH |
1.68 |
Fragment AZ-007 binding at a primary and secondary binding site of the the p53pT387/14-3-3 sigma complex |
| 6ZVC |
2.51 |
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 48h incubation |
| 6SIN |
1.64 |
Fragment AZ-020 binding at the p53pT387/14-3-3 sigma interface |
| 3SP5 |
1.8 |
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Cotylenol |
| 7NNE |
1.96 |
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 22 |
| 7AYF |
1.752 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-110 |
| 6HMU |
1.2 |
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C45 mutant bound to disulfide fragment PPI stabilizer 6 |
| 8BJG |
1.4 |
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 8 |
| 7NYE |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134 |
| 7O3A |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046 |
| 5MOC |
1.8 |
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
| 7OB8 |
1.8 |
Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide and stabilizer Fusicoccin-A |
| 6RM7 |
1.6 |
Fragment AZ-026 binding at the p53pT387/14-3-3 sigma interface |
| 6TWZ |
2.8 |
14-3-3 sigma complexed with a phosphorylated 16E6 peptide |
| 6TLG |
2.4 |
Ligand-free state of human 14-3-3 sigma isoform |
| 4DHN |
1.8 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 7NJ6 |
1.59 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1005 |
| 6Y40 |
1.75 |
14-3-3 Sigma in complex with phosphorylated PLN peptide |
| 7O6K |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080 |
| 7NIX |
1.9 |
14-3-3 sigma with AS160 binding site pT642 |
| 7NJB |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132 |
| 7B13 |
1.37 |
14-3-3sigma in complex with SHN3pS542 phosphopeptide crystal structure |
| 7OPW |
1.81 |
Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ136 |
| 7BA8 |
1.2 |
Cys-42-tethered stabilizer 10 of 14-3-3(sigma)/ERa PPI |
| 6G8I |
1.6 |
14-3-3sigma in complex with a R124beta3R mutated YAP pS127 phosphopeptide |
| 6RJL |
1.28 |
Fragment AZ-018 binding at the TAZpS89/14-3-3 sigma interface |
| 7B15 |
1.59 |
14-3-3sigma in complex with SHN3pT869 phosphopeptide crystal structure |
| 6T5F |
2.63 |
Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-195 |
| 6QDR |
1.615 |
Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide |
| 4JDD |
2.1 |
14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface |
| 6R5L |
1.884 |
Fragment AZ-006 binding at the p53pT387/14-3-3 sigma interface |
| 7BIW |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187 |
| 7O3S |
2.0 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045 |
| 6RWI |
1.65 |
Fragment AZ-002 binding at the p53pT387/14-3-3 sigma interface |
| 6XY5 |
1.3 |
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 5 |
| 4DHM |
1.7 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 7NV4 |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188 |
| 6YP8 |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033 |
| 6SLV |
1.9 |
Fragment AZ-013 binding at the p53pT387/14-3-3 sigma interface |
| 6HMT |
1.1 |
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 2 |
| 4IEA |
1.7 |
14-3-3 isoform sigma in complex with a phosphorylated C-RAF peptide |
| 7O3F |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117 |
| 7O5O |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165 |
| 4Y5I |
1.4 |
Crystal structure of C-terminal modified Tau peptide-hybrid 126B with 14-3-3sigma |
| 7NXW |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182 |
| 5MXO |
1.2 |
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide stabilized by Fusicoccin-A |
| 8BFC |
1.4 |
Binary structure of 14-3-3s and RND3 phosphopeptide |
| 6G8L |
1.37 |
14-3-3sigma in complex with a L132beta3L mutated YAP pS127 phosphopeptide |
| 6G8K |
1.25 |
14-3-3sigma in complex with a S131beta3S mutated YAP pS127 phosphopeptide |
| 6TM7 |
3.0 |
Human 14-3-3 sigma isoform in complex with PLP |
| 6Y8D |
1.51 |
14-3-3 Sigma in complex with phosphorylated caspase{pS164} peptide |
| 6Y58 |
1.904 |
Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (LBD) phosphopeptide |
| 7NIG |
1.9 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1008 |
| 7OBG |
1.8 |
Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide |
| 7NJ8 |
1.8 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1007 |
| 3SMN |
2.0 |
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fusicoccin A-THF |
| 1YZ5 |
2.8 |
The crystal structure of 14-3-3-sigma at 2.8 angstrom resolution |
| 7BGR |
1.8 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1016 |
| 4DHT |
1.8 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 6G8J |
1.47 |
14-3-3sigma in complex with a A130beta3A mutated YAP pS127 phosphopeptide |
| 3T0L |
1.6 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 8B2I |
1.4 |
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 4 |
| 6TLF |
2.9 |
human 14-3-3 sigma isoform in complex with IMP |
| 3O8I |
2.0 |
Structure of 14-3-3 isoform sigma in complex with a C-Raf1 peptide and a stabilizing small molecule fragment |
| 5OM0 |
3.2 |
CH2 chimera of human 14-3-3 sigma with the Gli1 phosphopeptide around Ser640 |
| 7O07 |
1.2 |
14-3-3sigma covalently bound to peptide (chloroacetamide-Cys interaction) |
| 8B4Q |
1.4 |
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 5 |
| 3P1Q |
1.7 |
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 Peptide and stabilizer fusicoccin A |
| 7NYF |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131 |
| 7BA6 |
1.4 |
Cys-42-tethered stabilizer 8 of 14-3-3(sigma)/ERa PPI |
| 7NFW |
1.19 |
Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide |
| 7BGV |
1.683 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1012 |
| 4DHP |
1.75 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 6YIB |
1.7 |
14-3-3 sigma in complex with SMAD3 pS423 peptide |
| 6QHL |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 |
| 4DAU |
2.0 |
Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif I |
| 7NR7 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111 |
| 3P1P |
1.95 |
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide |
| 7NM9 |
1.7 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110 |
| 7NIF |
1.71 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-011 |
| 7BMC |
2.0 |
Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide and stabilizing Fusicoccin A |
| 8BJN |
1.4 |
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 6 |
| 7OR5 |
1.8 |
Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ162 |
| 7NXY |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181 |
| 6YPL |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037 |
| 6RKI |
1.88 |
Fragment AZ-023 binding at the p53pT387/14-3-3 sigma interface |
| 3P1O |
1.9 |
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilisator Fusicoccin A |
| 7NLA |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119 |
| 7OR8 |
1.8 |
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ136 |
| 7OQ9 |
1.8 |
Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ136 |
| 4Y32 |
1.7 |
Crystal structure of C-terminal modified Tau peptide-hybrid 109B with 14-3-3sigma |
| 7BA5 |
1.45 |
Cys-42-tethered stabilizer 7 of 14-3-3(sigma)/ERa PPI |
| 6G6X |
1.13 |
14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide |
| 4Y3B |
1.8 |
Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma |
| 7NXS |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184 |
| 7BJW |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154 |
| 7O6J |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083 |
| 5LTW |
4.5 |
Complex of human 14-3-3 sigma CLU1 mutant with phosphorylated heat shock protein B6 |
| 7OQ8 |
1.43 |
Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ178 |
| 3SMK |
2.1 |
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Cotylenin A |
| 7BKH |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153 |
| 7AZ2 |
1.081 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1014 |
| 3SMO |
1.8 |
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Fusicoccin J aglycone |
| 7OR3 |
1.8 |
Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ136 |
| 7NQP |
1.24 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009 |
| 6FBY |
1.5 |
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2b with 14-3-3sigma |
| 7PWT |
2.312 |
Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptor alpha phosphopeptide, stabilised by pyrrolidone derivative 228 |
| 8BM5 |
1.4 |
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 7 |
| 7OQG |
1.5 |
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ136 |
| 6Y3M |
1.5 |
14-3-3 Sigma in complex with phosphorylated ATPase peptide |
| 7NMW |
1.5 |
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 40 |
| 3P1S |
1.65 |
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer fusicoccin A |
| 7OBK |
1.8 |
Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide |
| 3MHR |
1.15 |
14-3-3 sigma in complex with YAP pS127-peptide |
| 7O5P |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166 |
| 6YQ2 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129 |
| 6FCP |
1.45 |
Crystal structure of 14-3-3 sigma in complex with Shroom3 P1244L |
| 6T80 |
2.99 |
Human 14-3-3 sigma fused to the AANAT peptide including phosphoserine-205 |
| 6Y3R |
1.5 |
14-3-3 Sigma in complex with phosphorylated (Thr391) Gab2 peptide |
| 6Y3O |
1.5 |
14-3-3 Sigma in complex with phosphorylated CAMKK2 peptide |
| 6QZS |
1.9 |
14-3-3 sigma in complex with FOXO1 pS256 peptide |
| 6HKB |
1.7 |
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 3 |
| 5LU1 |
2.4 |
Human 14-3-3 sigma CLU3 mutant complexed with short HSPB6 phosphopeptide |
| 7OQA |
1.8 |
Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ162 |
| 7NRL |
1.8 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1032 |
| 7PWZ |
2.5 |
Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptoralpha phosphopeptide, stabilised by Pyrrolidone1 derivative 228 |
| 7NMH |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070 |
| 7BA9 |
1.48 |
Cys-42-tethered stabilizer 11 of 14-3-3(sigma)/ERa PPI |
| 7NN2 |
1.8 |
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 41 |
| 5N5T |
1.8 |
14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV2 |
| 7O59 |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192 |
| 7NVI |
1.2 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186 |
| 6SLW |
2.0 |
Fragment AZ-004 binding at the TAZpS89/14-3-3 sigma interface |
| 8B2K |
1.4 |
Ternary structure of 14-3-3s, RND3 phosphopeptide and dual-reactive compound 10 |
| 6HHP |
1.802 |
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 1 |
| 6S3C |
2.0 |
Fragment AZ-019 binding at the p53pT387/14-3-3 sigma interface |
| 6W0L |
2.3 |
Henipavirus W protein interacts with 14-3-3 to modulate host gene expression |
| 7ORT |
2.33 |
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ176 |
| 7NIZ |
1.48 |
Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide and ligands Fusicoccin-A and WR-1065 |
| 6T5H |
2.04 |
Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-57 |
| 7OQS |
1.34 |
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ177 |
| 7AXN |
1.4 |
14-3-3 sigma in complex with Pin1 binding site pS72 and covalently bound TCF521-026 |
| 6Y8A |
1.5 |
14-3-3 Sigma in complex with phosphorylated camkk2{pS511} peptide |
| 6SIP |
1.60045 |
Fragment AZ-011 binding at the p53pT387/14-3-3 sigma interface |
| 6SIQ |
1.60121 |
Fragment AZ-012 binding at the p53pT387/14-3-3 sigma interface |
| 6RHC |
1.2 |
Fragment AZ-003 binding at the TAZpS89/14-3-3 sigma interface |
| 6Y1D |
1.38 |
Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (DBD) phosphopeptide |
| 6SIO |
1.60418 |
Fragment AZ-017 binding at the p53pT387/14-3-3 sigma interface |
| 4QLI |
1.45 |
A novel phospho-switch in the linker region of the snail zinc finger protein which regulates 14-3-3 association, DNA binding and epithelial-mesenchymal differentiation |
| 8BI7 |
1.4 |
Binary structure of 14-3-3s and PKR phosphopeptide |
| 7BJF |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069 |
| 5MY9 |
1.327 |
Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS935 |
| 6YR5 |
2.25 |
14-3-3 sigma in complex with hDMX-367 peptide |
| 4DHU |
1.67 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 7BG3 |
1.4 |
14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2046 |
| 6Y1J |
1.127 |
14-3-3 sigma in complex with IkappaBalpha pS63 peptide |
| 3UX0 |
1.75 |
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer Fusicoccin H |
| 5OKF |
3.2 |
CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with self-bound phosphopeptides |
| 6YP2 |
1.8 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011 |
| 5MYC |
1.459 |
Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS910 |
| 5N5R |
1.801 |
14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV1 |
| 7NK3 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128 |
| 4DHS |
1.74 |
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening |
| 6FI5 |
1.7 |
Crystal structure of C-terminal modified Tau peptide-hybrid 3.2d with 14-3-3sigma |
| 6YPY |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123 |
| 6S39 |
1.88 |
Fragment AZ-018 binding at the p53pT387/14-3-3 sigma interface |
| 7OQ7 |
1.6 |
Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ162 |
| 7NM3 |
1.4 |
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135 |
| 1YWT |
2.4 |
Crystal structure of the human sigma isoform of 14-3-3 in complex with a mode-1 phosphopeptide |
